Global Point of Care
BACK
  • United States
Home > Products

C. DIFF QUIK CHEK COMPLETE®

The C. DIFF QUIK CHEK COMPLETE® test provides a comprehensive diagnostic picture unlike any other standalone test. Incoming samples are simultaneously tested for GDH and Toxins A & B as recommended by the updated IDSA/SHEA Guidelines1 and ESCMID Guidelines2, providing actionable C. difficile results in less than 30 minutes.

Benefits

Accurate

The C. DIFF QUIK CHEK COMPLETE® test provides a final answer on up to 90 percent of samples in one test

Rapid

The test yields results in less than 30 minutes

Flexible

Samples may be performed in batches or individually for on demand testing

Convenient

The test works with any specimen consistency and with samples stored in transport media such as Cary Blair or C&S

Helpful Documents
  • The antigen portion of the C. DIFF QUIK CHEK COMPLETE® test detected 98.7% of the cyto-toxicity tissue culture-positive samples.3
  • The Negative Predictive Value for the toxin portion compared to cyto-toxicity tissue culture was 98.1%3
  • Toxin sensitivity 87.8% compared to cyto-toxicity tissue culture3
  • Toxin specificity 99.4% compared to cyto-toxicity tissue culture3
  • Kit Sizes=25 tests or 50 tests3
C. DIFF QUIK CHEK COMPLETE® Code
  (OUS) T30525C (25T)
  (OUS) T30550C (50T)
  (US) 30525C (25T)
  (US) 30550C (50T)

C. DIFF QUIK CHEK COMPLETE®  is developed and manufactured by TECHLAB Inc., under license.

1. Updated IDSA/SHEA guidelines published in 2018 recommend:

  • Against the use of NAAT alone when there are no pre-agreed institutional criteria for patient stool submission, due to inadequate positive predictive value
  • Use of a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) for all specimens received in the clinical laboratory whether there are or are no pre-agreed institutional criteria for patient stool submission.
  • Or screening samples simultaneously with both a GDH and toxin A/B EIA with an assay that includes both these targets in one system (C. DIFF QUIK CHEK COMPLETE®).

2. Updated ESCMID guidelines published in 2016 recommend:

  • Against the use of a single rapid test as a standalone test, due to inadequate positive predictive value.
  • The use of a 2-step algorithm starting with either GDH EIA or NAAT. Samples with a negative first test result can be reported as negative. Samples with a positive first test result should be tested further with a Toxin A & B EIA.
  • Or screen samples simultaneously with both a GDH and toxin A/B EIA with an assay that includes both these targets in one system (C. DIFF QUIK CHEK COMPLETE®).

3. C. DIFF QUIK CHEK COMPLETE® Package Insert

Stay informed

Sign up to receive valuable updates from Abbott.

Click here to signup

Need Technical Support?

Click here to get in touch with our technical support team.

   

False
accessibility

   

YesNo
accessibility

   

YesNo
accessibility

   

YesNo
More Info